J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Prophylactic Steroid Use with Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Olalekan O. Oluwole,Krimo Bouabdallah,Javier Munoz,Sophie de Guibert,Julie M. Vose,Nancy L. Bartlett,Yi Lin,Abhinav Deol,Peter A. McSweeney,Andre Goy,Marie José Kersten,Caron A. Jacobson,Umar Farooq,Monique C. Minnema,Catherine Thieblemont,John M. Timmerman,Patrick J. Stiff,Irit Avivi,Dimitrios Tzachanis,Jenny J. Kim,Zahid Bashir,Jeff McLeroy,Lovely Goyal,Lisa Johnson,Yan Zheng,Tom van Meerten +25 more
Journal ArticleDOI
Oncology Treatment in the Era of COVID-19: We Cannot Afford to Hit the Pause Button.
Sarah A. Holstein,Julie M. Vose +1 more
TL;DR: Given the expected duration of the pandemic, it is imperative that treatment of the patient's cancer remain the priority and that advances in drug development continue through appropriately designed clinical trials.
Journal ArticleDOI
Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma
Adam K. Ahrens,Nagendra K. Chaturvedi,Ashima Shukla,Tara M. Nordgren,Ganapati V. Hegde,Julie M. Vose,Shantaram S. Joshi +6 more
TL;DR: A significant antilymphoma effect of targeting PLK1 in therapy-resistant MCL cells and primary MCL Cells from refractory patients is demonstrated and results suggest that PLK 1 is a viable target for the treatment of therapy- resistant MCL.
Journal ArticleDOI
Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)
Jayadev Manikkam Umakanthan,Lori J. Maness,Jiangtao Luo,Avyakta Kallam,James O. Armitage,Philip J. Bierman,Julie M. Vose,R. Gregory Bociek,Matthew A. Lunning,Krishna Gundabolu,Vijaya Raj Bhatt +10 more
Journal ArticleDOI
Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission
Julie M. Vose,Ravi Pingali,Nina Wagner-Johnson,Fausto R. Loberiza,Timothy S. Fenske,Sarah Jewell,Martin Bast,Nancy L. Bartlett,James O. Armitage +8 more
TL;DR: The majority of relapses in patients with DLBCL after achieving CR1 to an R-CHOP or similar regimen occur when signs or symptoms of the disease lead to evaluation and are not detected by RSI, indicating that the use of RSI in patients in first complete remission in CR1 has limited clinical utility.